Babis Andreadis, MD
Chimeric antigen receptor (CAR) T-cell therapy exploded onto the scene in 2017 with the approval of tisagenlecleucel (Kymriah) in acute lymphoblastic leukemia (ALL) and axicabtagene ciloleucel (axi-cel; Yescarta) in non-Hodgkin lymphoma (NHL).
State of the Science SummitTM on Hematologic Malignancies, Babis Andreadis, MD, associate professor of clinical medicine, Department of Medicine, director, Clinical Research Support Office, University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, reflected on the successes seen with CAR T-cell development in the past year and the use of CAR T-cell therapy in patients with NHL.
OncLive: Please provide an overview of your presentation on CAR T-cell therapy in NHL.
: We are living in an exciting era in lymphoma therapy because of the recent developments in immunotherapy, specially CAR T-cell therapies. In 2017, we saw the approval of 2 novel therapies in patients with ALL and diffuse large B-cell lymphoma. My talk focused on how these therapies work and what are the expected management complications and toxicities associated with them. In the lymphoma sphere, we know that both therapies can produce 30% to 40% long-term responders, meaning people who are out 6 months or more with a complete response. The goal is to determine whether those patients can be seen as longer-term responders and eventually be cured. We think CAR T-cell therapy has the ability to do that.
... to read the full story